About revelation biosciences inc - REVB
Revelation Biosciences, Inc. engages in the development of immunologic-based therapies for the prevention and treatment of disease. Its product candidates include REVTx-99b, its lead therapeutic candidate being developed for allergic rhinitis and chronic nasal congestion, REVDx 501, a rapid home use diagnostic that can be used to detect any respiratory viral infection, regardless of virus type or strain, without the need for specialized instrumentation, and REVTx 200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. The company was founded on November 20, 2019 and is headquartered in San Diego, CA.
REVB At a Glance
Revelation Biosciences, Inc.
4660 La Jolla Village Drive
San Diego, California 92122
| Phone | 1-650-800-3717 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -8,913,649.00 | |
| Sector | Health Technology | Employees | 8 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
REVB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 0.572 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.881 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | -0.094 |
REVB Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,114,206.125 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
REVB Liquidity
| Current Ratio | 5.411 |
| Quick Ratio | 5.411 |
| Cash Ratio | 5.355 |
REVB Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -97.925 |
| Return on Equity | -131.379 |
| Return on Total Capital | -92.775 |
| Return on Invested Capital | -124.726 |
REVB Capital Structure
| Total Debt to Total Equity | 8.428 |
| Total Debt to Total Capital | 7.773 |
| Total Debt to Total Assets | 6.447 |
| Long-Term Debt to Equity | 8.168 |
| Long-Term Debt to Total Capital | 7.533 |